{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:59:48Z","timestamp":1787504388097,"version":"build-2736575974"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193846","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T13:39:09Z","timestamp":1521121149000},"page":"e0193846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-2451","authenticated-orcid":true,"given":"Ken","family":"Iseri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"V LoCascio","year":"1990","journal-title":"Bone Miner"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"TP van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Glucocorticoid-Induced Bone Disease","volume":"365","author":"RS Weinstein","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","article-title":"Glucocorticoid-induced osteoporosis: who to treat with what agent?","volume":"11","author":"R Rizzoli","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"SR Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"JP Brown","year":"2011","journal-title":"J Bone Miner Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Y Suzuki","year":"2014","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"HK Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2169\/internalmedicine.56.7797","article-title":"Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids","volume":"56","author":"M Sawamura","year":"2017","journal-title":"Intern Med"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archdermatol.2011.354","article-title":"Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study","volume":"148","author":"S-I Tee","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","article-title":"Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice","volume":"58","author":"W Yao","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/me.2009-0069","article-title":"Minireview: live and let die: molecular effects of glucocorticoids on bone cells","volume":"23","author":"LC Hofbauer","year":"2009","journal-title":"Mol Endocrinol"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"RK Dore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2015.03.002","article-title":"Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial","volume":"75","author":"CC Mok","year":"2015","journal-title":"Bone"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bone.2009.12.032","article-title":"Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate","volume":"46","author":"AL Burshell","year":"2010","journal-title":"Bone"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00198-005-2032-z","article-title":"Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club","volume":"17","author":"J-P Devogelaer","year":"2006","journal-title":"Osteoporos Int"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"KG Saag","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.62","article-title":"Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan","volume":"90","author":"T-C Lin","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"N Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/TP.0000000000001547","article-title":"Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab","volume":"101","author":"M Bonani","year":"2017","journal-title":"Transplantation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:48:53Z","timestamp":1540342133000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193846"}},"subtitle":[],"editor":[{"given":"Rosa Maria Affonso","family":"Moys\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193846","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]}}}